ImmuneOncia Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
424870
- Share Price
-
$1.79
- (As of Monday Closing)
ImmuneOncia General Information
Description
Immuneoncia Therapeutics Inc is an immuno-oncology-centric biopharmaceutical company. The company focuses on developing immunotherapies for cancer treatment.
Contact Information
Website
www.immuneoncia.comCorporate Office
- 25, Tapsil-ro 35beon-gil
- Giheung-gu
- Yongin, Gyeonggi 17084
- South Korea
Corporate Office
- 25, Tapsil-ro 35beon-gil
- Giheung-gu
- Yongin, Gyeonggi 17084
- South Korea
ImmuneOncia Stock Performance
As of 16-Nov-2026, ImmuneOncia’s stock price is $1.79. Its current market cap is $164M with 91.3M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.79 | $1.84 | $1.58 - $10.16 | $164M | 91.3M | 628K | -$0.26 |
ImmuneOncia Financials Summary
As of 30-Jun-2026, ImmuneOncia has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 199,491 | 647,290 | ||
| Revenue | 0 | 78 | 480 | 84 |
| EBITDA | (20,319) | (19,094) | (3,898) | 6,982 |
| Net Income | (20,194) | (19,227) | (4,168) | 6,780 |
| Total Assets | 68,142 | 23,018 | 17,784 | 26,225 |
| Total Debt | 27 | 48 | 65 | 106 |
ImmuneOncia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ImmuneOncia Comparisons
Industry
Financing
Details
ImmuneOncia Competitors (22)
One of ImmuneOncia’s 22 competitors is NovaBridge Biosciences, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NovaBridge Biosciences | Formerly VC-backed | Rockville, MD | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
ImmuneOncia Patents
ImmuneOncia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024430244-A1 | Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody | Active | 22-May-2024 | ||
| AU-2024430244-B2 | Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody | Active | 22-May-2024 | ||
| EP-4674869-A1 | Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody | Pending | 22-May-2024 | ||
| EP-4674869-A4 | Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody | Pending | 22-May-2024 | ||
| WO-2025244201-A1 | Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody | Pending | 22-May-2024 | C07K16/2803 |
ImmuneOncia Signals
ImmuneOncia ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
ImmuneOncia FAQs
-
When was ImmuneOncia founded?
ImmuneOncia was founded in 2016.
-
Where is ImmuneOncia headquartered?
ImmuneOncia is headquartered in Yongin, South Korea.
-
What is the size of ImmuneOncia?
ImmuneOncia has 25 total employees.
-
What industry is ImmuneOncia in?
ImmuneOncia’s primary industry is Drug Discovery.
-
Is ImmuneOncia a private or public company?
ImmuneOncia is a Public company.
-
What is ImmuneOncia’s stock symbol?
The ticker symbol for ImmuneOncia is 424870.
-
What is the current stock price of ImmuneOncia?
As of 16-Nov-2026 the stock price of ImmuneOncia is $1.79.
-
What is the current market cap of ImmuneOncia?
The current market capitalization of ImmuneOncia is $164M.
-
Who are ImmuneOncia’s competitors?
NovaBridge Biosciences, Altimmune, Lisata Therapeutics, AVEO Oncology, and CytomX Therapeutics are some of the 22 competitors of ImmuneOncia.
-
What is ImmuneOncia’s annual earnings per share (EPS)?
ImmuneOncia’s EPS for 12 months was -$0.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process